CP-COV03 has a pharmacological action that helps human cells to eliminate viruses by promoting ‘autophagy’ mechanism. Credit: PixxlTeufel from Pixabay.

Hyundai Bioscience has launched the Phase II clinical trial of a new broad-spectrum antiviral agent, CP-COV03, for the treatment of Covid-19 patients.

The antiviral drug, developed in Korea as a universal treatment for diseases including Covid-19, has the ‘viral removal’ mechanism that is applicable to all viral infections.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Existing antiviral agents act on only specific viruses.

CP-COV03 is administered orally and comprises active ingredient niclosamide. It has a pharmacological action that promotes ‘autophagy’ mechanism to help human cells eliminate viruses.

In this process, cells identify the virus as a foreign substance and remove it themselves.

Hyundai Bioscience said in a statement: “If CP-COV03 is confirmed to be effective against Covid-19 in this clinical study, it means that a universal antiviral drug is born not only for Covid-19 and its variants, but also for almost all other viruses such as influenza, hepatitis, AIDS, Ebola, and herpes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CP-COV03, which is currently evaluated in Phase II clinical trial, is similar to the human efficacy test of penicillin conducted in 1941, in several ways.

Hyundai Bioscience further added: “The discovery of a substance with the mechanism that kills bacteria led to the 20th century medicine called penicillin and that CP-COV03 with a mechanism to eliminate viruses by promoting autophagy will be the first universal antiviral drug like penicillin.”

As a broad-spectrum antiviral agent, CP-COV03 is expected to enable a quick preemptive treatment for viral infection, thereby preventing pandemics.

In December last year, Hyundai Bioscience reported that a combination of CP-COV03 with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19, in a study.